Jump to content

Thioproscaline

From Wikipedia, the free encyclopedia
Thioproscaline
Clinical data
Other namesTP; 4-Thioproscaline; 4-TP; 3,5-Dimethoxy-4-propylthiophenethylamine; 4-Propylthio-3,5-dimethoxyphenethylamine
Routes of
administration		Oral[1]
Drug classSerotonergic psychedelic; Hallucinogen
ATC code
  • None
Pharmacokinetic data
Onset of action>2 hours[1]
Duration of action10–15 hours[1]
Identifiers
  • 2-[3,5-dimethoxy-4-(propylsulfanyl)phenyl]ethan-1-amine
CAS Number
PubChem CID
ChemSpider
UNII
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC13H21NO2S
Molar mass255.38 g·mol−1
3D model (JSmol)
  • COc1cc(cc(OC)c1SCCC)CCN
  • InChI=1S/C13H21NO2S/c1-4-7-17-13-11(15-2)8-10(5-6-14)9-12(13)16-3/h8-9H,4-7,14H2,1-3H3 checkY
  • Key:BQFDSMXQCJFKCH-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Thioproscaline (TP), or 4-thioproscaline (4-TP), also known as 3,5-dimethoxy-4-propylthiophenethylamine, is a psychedelic drug of the phenethylamine and scaline families related to mescaline.[1][2][3][4] It is the analogue of proscaline in which the propoxy group at the 4 position has been replaced with a propylthio group.[1][2][3]

In his book PiHKAL (Phenethylamines I Have Known and Loved) and other publications, Alexander Shulgin lists thioproscaline's dose as 20 to 25 mg orally and its duration as 10 to 15 hours.[1][2][3] Its onset is more than 2 hours.[1] The drug has approximately 10 to 16 times the potency of mescaline.[2][3][4][1] The effects of thioproscaline have been reported to include extremely rich closed-eye imagery, quite a bit of open-eye visuals, body load, body heaviness, heavy pressure at the back of the neck, feeling vulnerable, dizziness, and hyperreflexia.[1][4] It was remarked that the psychoactive effects did not seem worth the physical side effects, although it was suggested that lower doses might be better.[1][4]

The chemical synthesis of thioproscaline has been described.[1][4]

Thioproscaline was first described in the scientific literature by Alexander Shulgin and Peyton Jacob III in 1984.[4] Subsequently, it was described in greater detail by Shulgin in PiHKAL in 1991.[1] The drug is not a controlled substance in Canada as of 2025.[5]

See also

[edit]

References

[edit]
  1. ^ a b c d e f g h i j k l Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628. https://www.erowid.org/library/books_online/pihkal/pihkal174.shtml
  2. ^ a b c d Jacob P, Shulgin AT (1994). "Structure-Activity Relationships of the Classic Hallucinogens and Their Analogs". In Lin GC, Glennon RA (eds.). Hallucinogens: An Update (PDF). National Institute on Drug Abuse Research Monograph Series. Vol. 146. National Institute on Drug Abuse. pp. 74–91. PMID 8742795. Archived from the original on 13 July 2025.
  3. ^ a b c d Shulgin AT (2003). "Basic Pharmacology and Effects". In Laing RR (ed.). Hallucinogens: A Forensic Drug Handbook. Forensic Drug Handbook Series. Elsevier Science. pp. 67–137. ISBN 978-0-12-433951-4. Archived from the original on 13 July 2025.
  4. ^ a b c d e f Jacob P, Shulgin AT (July 1984). "Sulfur analogues of psychotomimetic agents. 3. Ethyl homologues of mescaline and their monothio analogues". J Med Chem. 27 (7): 881–888. doi:10.1021/jm00373a013. PMID 6737431.
  5. ^ "Controlled Drugs and Substances Act". Department of Justice Canada. Retrieved 19 January 2026.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Thioproscaline&oldid=1338626200"